SUMMARY Nineteen subjects were investigated as a result of apnoea following the administration of suxamethonium occurring in one member of the family. Examination of the blood for cholinesterase activity, dibucaine number, and fluoride number was carried out Sleep was induced with 100 mg methohexitone sodium intravenously followed by intravenous injection of 100 mg suxamethonium chloride. After intubation anaesthesia was maintained with nitrous oxide-oxygen (5: 3 1/rn) and 0 * 5 to 1 0 % halothane. Apnoea persisted for 90 minutes despite ventilation with 5 to 6 1/m oxygen and full respiration did not return for a further 30 minutes. A peripheral nerve stimulator was not available. Blood gas analysis carried out half an hour after apnoea showed a pH of 7 05, PCo2 12-5 kPa (94 mmHg), Po2 28 1 kPa (211 mmHg), plasma bicarbonate 22.9 mmol/l, base excess -10 mmol/l. One hour later when recovery was taking place the values were pH 7 * 32, Pco2 6 * 0 kPa (44 mmHg), Po2 20.0 kPa (150 mmHg), plasma bicarbonate 19 mmol/l, base excess -6 mmol/l. The plasma cholinesterase, as repeated after discharge, was 22 units, the dibucaine number 18, and fluoride number 17.
Suxamethonium (succinyldicholine, Scoline), a depolarising neuromuscular blocking agent, is widely used as a short acting muscular relaxant. It is hydrolysed by the enzyme acylcholine acylhydrolase with the code number E.C.3. 1.1.8, commonly known as plasma cholinesterase (ChE). The average adult dose of 1 mg/kg body weight produces respiratory paralysis by peripheral action of two to four minutes' duration. A period of apnoea lasting more than 10 minutes is considered abnormal.
Before incriminating a genetic abnormality of ChE, apnoea of central origin, or resulting from the anaesthetic agent or technique, or certain antibiotics,1 2 or abdominal surgery itself,3 have to be excluded. Moreover various diseases and drugs can affect ChE. 4 The following case illustrates the latent hazard which every anaesthetist fears when, following suxamethonium used routinely and in a single dose in a fit person during the course of a normal operating list, apnoea occurred as a result of a genetic abnormality of the ChE.
Case report
A housewife aged 50, weighing 53 kg, was admitted to hospital for a D and C, curettage and cauterisation of the cervix. Premedication was an intramuscular injection of pethidine 50 mg and atropine 0-6 mg.
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Methods
ChE activity (100 x change in pH in one hour) was estimated with benzoylcholine as substrate using the group.bmj.com on June 20, 2017 -Published by http://jmg.bmj.com/ Downloaded from ultraviolet spectrophotometer. 5 The differential inhibition by dibucaine hydrochloride6 and sodium fluoride7 enabled the dibucaine number (DN) and fluoride number (FN) to be determined.
Results
The figure sets out the relationship of the members of the family to the proband, together with their genotypes. Table 1 shows the cholinesterase activity, details of the inhibition studies, genotypes, and suxamethonium sensitivity for each of the members tested. It will be seen that of the 19 subjects examined nine were considered to be sensitive to suxamethonium.
Discussion
Although the blood gas analysis showed that the patient was inadequately ventilated, the primary cause of the prolonged apnoea was considered to be a genetic abnormality of the cholinesterase.
There are four allelic genes of importance to the anaesthetist which control ChE activity and which function at the same locus, designated E1 using the nomenclature of Motulsky.8 In the case of IV * 2, a female child aged 11 months, blood examination is being postponed until the age of 5. In the meantime, since it is known that at birth the ChE is low,'6-2' the parents and the general practitioner were advised that suxamethonium should be avoided, as suxamethonium apnoea in infancy, although rare, has been recorded. 22 
